Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.

Previously, tumor-type- or therapy-type-specific scoring systems were used for pathologic response assessment.

以前，针对肿瘤类型或治疗类型的特定评分系统被用于病理反应评估。

The goal of this effort is to update, harmonize, and standardize the emerging system(s) for pathologic response assessment and data capture.

本项工作的目标是更新、协调和标准化新兴的病理反应评估和数据捕获系统。

materials_and_methods

Leaders in pathology, oncology, and surgery, including those from the Society for Immunotherapy of Cancer's Pan-tumor Harmonization of Pathologic Response Assessment (PATHdata) efforts and the International Neoadjuvant Melanoma Consortium (INMC), convened to develop updated consensus guidelines for pathologic response assessment, including specimen handling and tissue submission, scoring, and reporting.

病理学、肿瘤学和外科领域的领导者，包括来自癌症免疫治疗学会的全瘤病理反应评估（PATHdata）努力和国际新辅助黑色素瘤联盟（INMC）的代表，聚集在一起制定了更新的病理反应评估共识指南，包括标本处理和组织提交、评分和报告。

This paper builds upon previous recommendations, which are updated based on histologic features associated with patient outcomes.

本文在先前推荐的基础上进行了扩展，这些推荐根据与患者预后相关的组织学特征进行了更新。

Specific attention was paid to commonalities across tumor types, as well as tumor-type-specific considerations.

特别关注了肿瘤类型之间的共同点，以及特定肿瘤类型的考虑因素。

Results

A revised and standardized approach to tissue submission is recommended, including total submission of tumors ≤3 cm in size for histologic analysis.

建议采用修订和标准化的组织提交方法，包括对≤3厘米大小的肿瘤进行全部提交以进行组织学分析。

Additional guidance is provided for larger tumors.

对于较大肿瘤，提供了额外的指导。

Pathologic response is quantified through assessments of percentage of residual viable tumor (%RVT), necrosis, and regression.

病理反应通过评估残余可存活肿瘤的百分比（%RVT）、坏死和退缩来量化。

Descriptions of histologic features to be scored are provided together with a standardized reporting template.

提供了需要评分的组织学特征描述，以及一个标准化的报告模板。

Recommendations regarding collecting additional key datapoints are also made, to allow continued, extended validation of this pan-tumor approach.

还提出了关于收集额外关键数据点的建议，以便持续、长期验证这种泛肿瘤方法。

Conclusions

As pathologic response emerges as a surrogate endpoint for long-term clinical outcomes and to help inform adaptive adjuvant therapy decisions in routine clinical care, standardization is critical to facilitate consistent and reliable application.

随着病理反应作为长期临床结果的替代终点出现，并帮助在常规临床护理中告知适应性辅助治疗决策，标准化至关重要，以促进一致和可靠的运用。

This pan-tumor approach to scoring and reporting supports robust stratification of patient outcomes, facilitates comparisons across clinical trials and tumor types, enhances data collection, and establishes a foundation for identifying additional, clinically meaningful %RVT cut points.

这种针对所有肿瘤的评分和报告方法支持对患者结果进行稳健的分层，便于在临床试验和肿瘤类型之间进行比较，增强数据收集，并为识别额外的、临床有意义的%RVT切割点奠定了基础。